Stryker Corporation $SYK Shares Sold by Blair William & Co. IL

Blair William & Co. IL cut its position in shares of Stryker Corporation (NYSE:SYK) by 8.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 844,899 shares of the medical technology company’s stock after selling 74,606 shares during the quarter. Stryker comprises 0.8% of Blair William & Co. IL’s portfolio, making the stock its 24th biggest position. Blair William & Co. IL’s holdings in Stryker were worth $296,957,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Czech National Bank increased its position in shares of Stryker by 3.9% in the fourth quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock worth $31,898,000 after acquiring an additional 3,366 shares in the last quarter. Davis R M Inc. increased its position in shares of Stryker by 1.8% in the third quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock worth $51,285,000 after acquiring an additional 2,512 shares in the last quarter. Kepler Cheuvreux Suisse SA acquired a new stake in shares of Stryker in the third quarter worth $27,952,000. Daymark Wealth Partners LLC increased its position in shares of Stryker by 436.0% in the fourth quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock worth $16,119,000 after acquiring an additional 37,307 shares in the last quarter. Finally, Wealthcare Advisory Partners LLC increased its position in shares of Stryker by 265.2% in the fourth quarter. Wealthcare Advisory Partners LLC now owns 9,328 shares of the medical technology company’s stock worth $3,278,000 after acquiring an additional 6,774 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SYK has been the subject of several recent research reports. Leerink Partners dropped their price objective on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a research note on Friday, May 1st. Citigroup lowered their target price on Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. UBS Group lowered their target price on Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research note on Tuesday, March 17th. Finally, Evercore set a $355.00 target price on Stryker in a research note on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average target price of $395.33.

Stryker Price Performance

SYK opened at $310.71 on Wednesday. The company has a fifty day simple moving average of $315.51 and a 200 day simple moving average of $342.88. The firm has a market cap of $119.11 billion, a price-to-earnings ratio of 35.96, a PEG ratio of 1.97 and a beta of 0.78. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $404.87. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same quarter last year, the business earned $2.84 EPS. Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts expect that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is 40.74%.

Insider Buying and Selling at Stryker

In other Stryker news, VP M Kathryn Fink sold 3,500 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the completion of the transaction, the vice president directly owned 177 shares of the company’s stock, valued at $50,170.65. This trade represents a 95.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 323,264 shares of company stock worth $100,659,489 in the last 90 days. 4.60% of the stock is owned by corporate insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.